Two major news regarding Aurora Cannabis, Inc. kept investors optimistic about the long-term growth potential of Aurora Cannabis Inc. this week. Consequently, its stock trading on NYSE gained ample bullish momentum to attract attention.
The Edmonton, Canada, based Aurora Cannabis, Inc.’s stock turned bullish over the last few days after it announced that two of its facilities are now fully licensed by Health Canada for the production and sale of cannabis on February 25, 2019. According to the press release, Aurora Sky and MedReleaf Bradford facilities have received the license and add over 128,000 kg per year in capacity for the company.
Commenting on the approval from Health Canada, Terry Booth, the Chief Executive Officer of Aurora Cannabis Inc. said that its recent harvests exceeded target yields and validated the long-held production philosophy of investing in high-tech and highly automated Cannabis production facilities.
The second news that stirred the market on February 27 was about acquiring 51% shares of Portugal’s Gaia Pharma Lda, effectively giving Aurora Cannabis Inc. the management control over the company. While the terms of the deal are not disclosed, sources indicated that Aurora Cannabis Inc. plans to establish a local facility in Portugal to produce medical cannabis and derivative products for the fast-growing European market.
It is worth mentioning that Gaia Pharma Lda recently won the approval from the Portuguese Health Ministry to build a European Union GMP-compliant cannabis cultivation facility. However, it will be now renamed as Aurora Portugal, Lda and act as the growth catalyst for Aurora Cannabis, Inc.’s ambitions in the legal Cannabis market in the European Union.
Although Aurora Cannabis, Inc.’s stock is trading with a price-to-earnings ratio of 35.88, it is natural for growth stocks to have such high P/E. With $7.48 billion in market capitalization, Aurora Cannabis Inc. is one of the most significant players in the newly regulated Cannabis industry in Canada. Moreover, with the acquisition of Gaia Pharma Lda, it appears that they are eying the long-term prospects of the industry in the international market.
This article was first published on: Feb 27, 2019